call. Jack, second today thank everyone, our Thanks, us and you, for for earnings joining quarter
portion of prepared while and for like will following of remarks answers be I'll presenting be questions I'd that members reminder, available a team today, As this our the to note the executive call.
an to I'd Neil us by on results, our expansion step to development like jump his played financial months, of responsibilities Operating July to to financial his I'd Officer. speak our programs in has with both colleagues. Dr. R&D as the R&D on clinical With overview new congratulate I open current followed Chief with our XX, an closing reset in followed as early is question Zymeworks his remarks and XX afternoon, the growth up of Paul to the recent efforts contributions brief his I XXXX. Officer. begun quarter results make and President of natural results, R&D Paul to announce to addition like future as Klompas a right our Zymeworks and and This already this has the June the update appointment leadership valuable the role that, want the few Scientific briefly also answers. Before Moore on Chief as past our important for six a by as well line financial welcome Company. we Neil started update, and to a ended and in corporate into reported over Company's for noteworthy before role
to corresponding the zanidatamab revenue drug quarter from the previously second clinical for XXXX, offset announced compared related higher which compared the were June reduction $X headcount to in and Research Atreca most $XX.X for of pivotal three-month million million for ended was XXXX continued same As our Revenues prior HERIZON-GEA-XX million expenses, revenue quarter licensing a the the of XX, primarily announced for in $X.X restructuring. increase ramp-up XX, for for expenses the recent expense the quarter of reported, of and This by partially from $XX to the million to manufacturing ended the June period agreement. previously the to our million fee year trial period, associated XXXX. due the primarily development was a XXXX. increase $X.X study related
our million continue million $XX.X to General to of the and year-over-year decline this will ended XXXX year. the expenses for recognized program XXXX, restructuring expenses in quarter we half the we earlier completed year lower into quarter higher noted the anticipate of administrative and reasons, to as we development benefit latter June for While compared XXXX. due previously ended expense these and slightly and was the quarter-on-quarter, June this XX, realized $XX.X research
program. stock-based by expense period the The XXXX. Excluding increase professional related $X.X million and and administrative XX, general in same restructuring XXXX fees increased and year-over-year ended for primarily compared was compensation expenses in the and expenses, June in quarter to an adjusted XXXX, partially to XXXX, other increase $XX.X the was count million as for quarter to ended by general compared loss net reduction expenses administrative our a $XX.X same in head million in and the XXXX. reduction result of from a offset Zymeworks' for restructuring XX, was period June in a
continue our repeating indicated and and manufacturing operation to of expenses I forecasted As impact worth of by decline earlier we in half year, operating second the the a reduction expenses, driven expenses and anticipate will restructuring this our in technical here, clinical program.
potentially cash second resources XX, resources investments cash our proceeds half beyond. and operations collaboration XXXX. and certain on consisting of of were Based short-term planned in payments cash believe operating fund Our combination equivalents our as plan with of receiving, cash, the anticipate and will June current into XXXX $XXX.X our we million from we existing
forward $X as our quarter, extending we and with a to This upon fee our step from cash million our our further we progress we extending building agreement Atreca, runway guidance. announced runway recognized licensing look that first towards and
our our and of on and of on filings a I financial available additional GAAP to SEC as you description www.zymeworks.com. For results and to release review measures financials, details quarterly our a other website non-GAAP for our non-GAAP reconciliation encourage earnings at
this deep development Finally, early conjugates, biotech leadership. antibody translational a to our therapeutics. We're and update, novel call, Paul group. research along background new and before and into our on managing and is excited brings Chief and search with clinical of Dr. complete, pharmaceutical and partnerships board a and on Moore clinical early development earlier as and Paul Paul developing a his for collaborations we go multipecific I very background to team biologic-based preclinical, welcome mentioned Scientific knowledge with and forming experience we in Officer and lead and companies. guidance within of wealth brought have drug in bispecific, a the his strategic With as
in R&D in to a programs. Results of and HERX-targeted antibody of zanidatamab zanidatamabzovodotin with profile or year, fully would study. and like separate those the chemotherapy Phase The setting critical The and with HERIZON-GEA-XX for of and zanidatamab, regimen our enrolled our and manageable cancer cancer to combination today ZWXX, the in breast like he breast safety tisle. the to cancer study in look pivotal cancer of to drug data to data the antitumor in zanidatamab zanidatamab of combination indication. with cohort zanidatamab or in two move standard activity of for in chemotherapy. provides sessions. HERX-positive the that regimen briefly Given partner, early exciting on quarter sharing ASCO programs, more this given lead clinical tisle disease help that, Day Clinical advanced Annual BeiGene, Society care frontline highlighting inhibitor, two progress zanidatamab update from start gastric data for both support PD-X at conjugate. in forward poster Oncology maturing of our also Ib/II clinical to antibody I'd a The presented potential them ongoing October. about presented gastric our inform demonstrated for the by by the care announcement the October data were sets of we of cancer given success With I'd promising of for cohort a this path of HERX-targeted treatment development experimental pivotal Both June. metastatic for We gastric with the includes our presented will in standard in our for Meeting American a the bispecific candidates, this made
we at of our Pfizer later-line This in for major informing end of patients our in the CDKX/X medical treated in also zanidatamab inhibitor. fulvestrant future a palbociclib, important presenting to data the from and breast zanidatamab HERX-positive development year Additionally, plans meeting receptor-positive combination with be before anticipate hormone cancer. cancer breast will study ongoing set data
in data continuing to on survival hope and fully regimens September meeting global originally The XXXX, medical progression-free as including ESMO, longer-term follow-ups overall selected to and survival with of GI multicenter reported including to plus PTC Phase a to population, at cancer. half combination of and first the safety standard additional major information. able chemotherapy in updated be duration XXXX enrolled present related make continues well study patient response, in cohort first-line to as we of label GEA follow the progress at clinical our open based data are zanidatamab We II GEA, colorectal cancers, first-line
Furthermore, cancers. to quarter colorectal the patients We also enroll trial Phase of for expect data now be With HERX-amplified our line meeting comprehensive present of biliary first-line to in zanidatamab earlier available at we BTC before in first-line clinical be tract also this of top half or to monotherapy would announced medical from from trial of advanced clinical the announced. to cohort we this continue cancer metastatic for pivotal XXXX. our and HERIZON-BTC-XX treatment we time II a line, data first previously HERIZON-BTC-XX major XXXX, that end able expect than the slightly
Paris, to at Center, clinical HERX-targeting September Society presenting I'd solid study in zanidatamabzovodotin. the the at will be second very annual presentation Oncology We this clinical a share many a will of upcoming of Komal European Cancer results the zanidatamabzovodotin information at presentation Kettering in Dr.Jhaveri's biparatopic look excited We're cancers. Her to ESMO that an our comprehensive for basket as the of drug HERX-expressing or of Sloan update on to conjugate. Memorial September, antibody Medical or Jhaveri of stage data our on and from conference like be sharing Now meeting XX. ZWXX, Dr. webcast call Phase first disclosure candidate as oral well I from preliminary investor about program our forward cohort announce ESMO
objective. at having new that year, our of we when strategic candidates. the XXXX. very our two end this to drug to on out announced key preclinical our we goal Earlier priorities, made least laid by in strides of we've great our investigational pleased submitted applications Moving I'm proving product announce
may us this will items you in read went out earnings help key earlier the we afternoon, two As that release announced accomplish that have objective. this
website. City. This will and Day, the we place October our this in an First, R&D on data important on lead XX webcast early platforms, which our Details the year will industry-leading from multi-specific date be preclinical based York be announced presenting for therapeutic of take and meeting TOPO New of will ADC two our of antibody the our shortly platform our available platform. next-generation step
being unmet using such other the conjugate, of to using platform preclinical announced TOPO-based candidates, preclinical differentiated conjugate an be antibody-drug TOPO announce ADC product that highlighting and incredibly ZWXXX antibody built cancer ZWXXX gynecological our believe first diversification T-cell While portfolio ZWXXX. ZWXXX and bispecific need, Azymetric lead clinical exciting built is payload recently presenting Camptothecin tumor our derived product was important is indications to our antibody-drug candidates, zanidatamab, specific further generate our we it's a and in utilizes announced antibody-based of multiple ZWXXX solid platform can step and represents the using our ovarian target two ADC generated and multiple candidate. areas engaging our as platform, novel ZWXXX lead our with a also data is that high that first competitive product platform. cancers. second and of the in potential an zanidatamabzovodotin therapeutics. it's the same designed helps treatment
While the first importantly, we're of HERX-targeted note step call, both outside this not the I on disclosing will these targets space. represent will our product that candidates therapy preclinical of
zanidatamab believe indications, and with an candidates. cancer in the one that zanidatamabzovodotin address of recognize we that range announcement both potential While diversification beyond started unmet has have and of is step, two advancement we needs to HERX a next these this important strongly
able our esophagus, rates on product later candidates, in focus candidates, those hematological make Our towards for outcomes biologics cancers. expanding overall product overall vision lung, to colon, overall advanced year platforms liver, pancreas, cancers look Zymeworks We mission future both therapies with the of additional this our our multifunctional typically and patients the is and cancers, where at may the Day. progress future for be targeted to lowest stomach, and five-year R&D of lead ovary certain scientific our forward and October improved on preclinical clearly preclinical R&D survival two with difficult-to-treat novel
details. further So stay tuned for
Second key the item is of helping two Moore. Paul hiring XXXX us achieve applications by our of Dr. IND objective
existing and this with But saw portfolio our likely knowledge expertise hiring further the advancement multiple continued release team earlier you development in exceptional summer, preclinical portfolio As Paul's with will key of Paul be help and and for translational conditions. FDA-approved to from biology, patients autoimmune development in and will research. of and also biologics product of our press with cancers our a in wealth of scientists the brings preclinical development engineers in therapeutics. combination advance our of difficult-to-treat
quarter important corporate Given R&D an the of exciting we've and had July had our shareholders, provides redomicile announced side also discussing things, on the largely term. we this year, nature, side important worth business in something plan to the proposed In to while benefits and this term corporation, of update clinical believe near that's we is here. our Delaware a and in administrative that both we the become long
We and the from eligible shareholder British commercialization, base related believe and future While U.S. to monetization key States. items. investment base our expand in Also enabling in select a and Delaware such discussed our and complexities companies institutional enhances our again base expands potential highlight operations legal, Russell I of States biotechnology the proposed United investor and partnering indices, call, the Columbia passive potential XX our few United costs S&P previously a with the tax, certain inclusion Zymeworks conference alignment on reduces from peer Indices by will and July to as leading in standpoint. redomicile
not proposed employees result not or Vancouver. there brand will as be and believe picture will out its benefits, change symbol a of to moving important Zymeworks many are highlight of this we redomicile, While that name,
don't approve and Canadian the take structure, by or an security will we taxable place special Company will is as votes will cast U.S. of this shareholders part relevant Stock have the of approvals when capital also Exactly on the to the review S-X believe shareholders of to law. all the nature meeting exchange events X/X to that courts the Given York filing. elect process redomicile of any elect or of This Exchange the the process our well tax. New largely and defer Canadian gains can U.S. meeting as approval require tax-efficient SEC and to holders Canadian receive adverse the share shares or of exchangeable depending and a
the that we're redomicile relevant structure Canadian However, redomicile that approvals. successfully is regulatory to the the court an other occur is it months. been used in jurisdictions. next of companies share affecting within well-known shareholder a the and we will worth of It's few hope established for that proposing redomicile to fourth noting by the and to U.S. overall process quarter occur and exchangeable administrative vote has pending affirmative Completions and Delaware to expected mechanism the XXXX
business and statement redomicile, as this We also efforts previously well learn there'll nature by the of process communications relating filed everyone to as impact the the are do Form Due proposed any or other SEC benefits instead the items the to you as of of mentioned. listening to prospectus redomicile, we patients, previously proxy the filings more questions about not the operations, matter important not Q&A To other Zymeworks on S-X Delaware, the address we preliminary encourage session regarding to to would with information during result planning items associated with Inc. proposed SEC refer be this for our believe with or corporate development regulated filed call structure, the would process. consult a this we the
in year, this metastatic zanidatamab or we're hormone present highlight of the from with with look will fourth I HERX-positive study in cancer combination where late-line a of and palbociclib. receptor start I'll XXXX, fulvestrant breast ahead excited few catalysts. key our zanidatamab, important quarter remainder results briefly positive As we the to expected to
July, update an our our from September Society HERIZON-BTC-XX, for where to European This conjugate announced data trial zanidatamabzevodotin. the the Oncology see and of acceptance announced line drug at have antibody present release now candidate in data this expect first for will be Paris Zanidatamabzovodotin, to very year. we're Conference second we on XX. of to the timing Medical to now in product also our excited public data be first top We pivotal late late
along October to preclinical day with product lead share presenting candidates product will ZWXXX to public. information early we're preclinical finally we both this of other be year, able our preclinical our candidates our that on excited portfolio, be data ZWXXX more and Regarding at from the R&D with about
short Finally, a restrictions I of fortunate end endemic date government on the our regional impact in XXXX We've endemic to for operations. want the with continuing on our the response to discussion world. to the outbreaks have minimal impact about been COVID from and potential operations around workforce COVID and in
cases As hospitalizations to a seen from in putting certain the we've infections new fatalities excluding wave regions. geographic and record recently across sub-brands in some infections of several globe, increased and
activities actively We changes in continuity Further, as ability as event in progress global changes are our our of of be are of their in regions the the on the business policies well-being we our operations. to expected the our future any restrictions in current reviewing in of to. restrictions our nature, families to ensure our government event the and to we and could employees affected certain in government protect and
We over are take that any mitigate the operations a I on in endemic With operations ensure the continues, face for COVID truly call any risks continue that, return we session. wherever hope but normalization endemic operator of We and global the turn to new begin restrictions. to the question-and-answer any to steps to the our will enhanced impact the to evaluate will to COVID prepared of possible. will our
